title: [Renin inhibition in hypertension].
abstract: Aliskiren is a novel molecule which blocks the renin-angiotensin-aldosterone system in its rate limiting step by renin inhibition. Aliskiren is validated as an antihypertensive drug in many countries based on its efficacy data. Although some surrogate endpoint trials suggest that its potential advantages based on its mechanism of action provide clinical benefit beyond its blood pressure-lowering effect, hard endpoint clinical trials to reveal its long-term effects are yet to be completed.
authors.affiliation: Department of Cardiology, Medicine Faculty of Ankara University, Ankara, Turkey. gulec99@yahoo.com
authors.forename: Sadi
authors.initials: S
authors.lastname: Güleç
mesh_terms: D000577:Amides / Q000494:pharmacology* / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D005650:Fumarates / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D012084:Renin-Angiotensin System / Q000187:drug effects*; D000092502:Renin Inhibitors
chemical_list: D000577:Amides; D000959:Antihypertensive Agents; D005650:Fumarates; D000092502:Renin Inhibitors; C446481:aliskiren